Infectious Disease

Vical Receives U.S. government contract to manufacture Ebola vaccine

Published in TB and Outbreaks Week, August 27th, 2002

Vical, Inc., (VICL) announced that the company has been awarded a contract to manufacture clinical-grade supplies of an experimental DNA vaccine against Ebola for initial clinical development planned by the Dale and Betty Bumpers Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Vical's president and CEO, Vijay B. Samant, said, "Over the last several years, Vical has developed significant expertise and infrastructure, and has become recognized as a reliable manufacturer of clinical-grade (cGMP) plasmid DNA. We are pleased to support the VRC's Ebola vaccine program, which has potential for prevention of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-08-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry